A citation-based method for searching scientific literature

Kazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori, Shinichiro Shimamatsu, Fumihiko Hirai, Tetsuzo Tagawa, Tatsuro Okamoto, Motoharu Hamatake, Yuko Tsuchiya-Kawano, Kohei Otsubo, Koji Inoue, Yasuto Yoneshima, Kentaro Tanaka, Isamu Okamoto, Yoichi Nakanishi, Masaki Mori. Int J Cancer 2021
Times Cited: 3







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
66

The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda,[...]. Eur J Cancer 2021
5
66

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, Sergio Bracarda, Massimo Di Maio, Raffaele Giusti, Olga Nigro, Diego L Cortinovis, Joachim G J V Aerts, Giorgia Guaitoli,[...]. Eur J Cancer 2021
5
66

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
Luis Paz-Ares, David Vicente, Ali Tafreshi, Andrew Robinson, Hector Soto Parra, Julien Mazières, Barbara Hermes, Irfan Cicin, Balazs Medgyasszay, Jerónimo Rodríguez-Cid,[...]. J Thorac Oncol 2020
74
33

Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Giannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, Alex Friedlaender, Marco Banini, Giuseppe Lo Russo, Panagiotis Baxevanos, Fausto Roila, Giuseppe Luigi Banna, Athina Christopoulou,[...]. Clin Lung Cancer 2021
4
33

Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer.
Yusuke Tomita, Tokunori Ikeda, Shinya Sakata, Koichi Saruwatari, Ryo Sato, Shinji Iyama, Takayuki Jodai, Kimitaka Akaike, Shiho Ishizuka, Sho Saeki,[...]. Cancer Immunol Res 2020
16
33

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J Hochmair, Philip Clingan, Steven F Powell,[...]. J Clin Oncol 2020
194
33

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
M Dietel, N Savelov, R Salanova, P Micke, G Bigras, T Hida, J Antunez, B Guldhammer Skov, G Hutarew, L F Sua,[...]. Lung Cancer 2019
33
33

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O Butler, Mary L Disis, Jérôme Galon, Leif G Hakansson, Brent A Hanks, Vaios Karanikas, Samir N Khleif,[...]. J Immunother Cancer 2017
121
33

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock. Mol Cancer Ther 2017
975
33

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker.
Nuray Akyüz, Anna Brandt, Alexander Stein, Simon Schliffke, Thorben Mährle, Julia Quidde, Eray Goekkurt, Sonja Loges, Thomas Haalck, Christopher Thomas Ford,[...]. Int J Cancer 2017
28
33

Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy.
Xia Wu, Xiaojie Wang, Yan Zhao, Kun Li, Bo Yu, Jianzhong Zhang. Int J Med Sci 2021
2
50

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L Sauter, Natasha Rekhtman,[...]. J Clin Oncol 2018
639
33

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
Evan J Lipson, Victor E Velculescu, Theresa S Pritchard, Mark Sausen, Drew M Pardoll, Suzanne L Topalian, Luis A Diaz. J Immunother Cancer 2014
134
33

Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.
Patrycja Pawlikowska, Vincent Faugeroux, Marianne Oulhen, Agathe Aberlenc, Tala Tayoun, Emma Pailler, Françoise Farace. J Thorac Dis 2019
16
33

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment.
Laura Muinelo-Romay, Maria Vieito, Alicia Abalo, Marta Alonso Nocelo, Francisco Barón, Urbano Anido, Elena Brozos, Francisca Vázquez, Santiago Aguín, Miguel Abal,[...]. Cancers (Basel) 2014
75
33

B cells are associated with survival and immunotherapy response in sarcoma.
Florent Petitprez, Aurélien de Reyniès, Emily Z Keung, Tom Wei-Wu Chen, Cheng-Ming Sun, Julien Calderaro, Yung-Ming Jeng, Li-Ping Hsiao, Laetitia Lacroix, Antoine Bougoüin,[...]. Nature 2020
404
33


Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
Benjamin M Larimer, Eric Wehrenberg-Klee, Frank Dubois, Anila Mehta, Taylor Kalomeris, Keith Flaherty, Genevieve Boland, Umar Mahmood. Cancer Res 2017
126
33


Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
33

Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab.
Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile,[...]. J Immunother Cancer 2019
33
33

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Mauro Poggio, Tianyi Hu, Chien-Chun Pai, Brandon Chu, Cassandra D Belair, Anthony Chang, Elizabeth Montabana, Ursula E Lang, Qi Fu, Lawrence Fong,[...]. Cell 2019
360
33

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Alice O Kamphorst, Rathi N Pillai, Shu Yang, Tahseen H Nasti, Rama S Akondy, Andreas Wieland, Gabriel L Sica, Ke Yu, Lydia Koenig, Nikita T Patel,[...]. Proc Natl Acad Sci U S A 2017
326
33

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Nicolas Guibert, Myriam Delaunay, Amélie Lusque, Nadia Boubekeur, Isabelle Rouquette, Estelle Clermont, Jean Mourlanette, Sandrine Gouin, Inge Dormoy, Gilles Favre,[...]. Lung Cancer 2018
95
33

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Zhijie Wang, Jianchun Duan, Shangli Cai, Miao Han, Hua Dong, Jun Zhao, Bo Zhu, Shuhang Wang, Minglei Zhuo, Jianguo Sun,[...]. JAMA Oncol 2019
198
33


Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.
Efimia Boutsikou, Kalliopi Domvri, Georgia Hardavella, Dora Tsiouda, Konstantinos Zarogoulidis, Theodoros Kontakiotis. Ther Adv Med Oncol 2018
33
33

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.
Adrien Costantini, Catherine Julie, Coraline Dumenil, Zofia Hélias-Rodzewicz, Julie Tisserand, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Jean-François Emile,[...]. Oncoimmunology 2018
62
33

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer.
Xiao-Xiao Peng, Ruoying Yu, Xue Wu, Shu-Yu Wu, Can Pi, Zhi-Hong Chen, Xu-Chao Zhang, Cun-Yi Gao, Yang W Shao, Li Liu,[...]. J Immunother Cancer 2020
45
33

Small Nuclear RNAs (U1, U2, U5) in Tumor-Educated Platelets Are Downregulated and Act as Promising Biomarkers in Lung Cancer.
Xiaohan Dong, Shanshan Ding, Miao Yu, Limin Niu, Linlin Xue, Yajing Zhao, Li Xie, Xingguo Song, Xianrang Song. Front Oncol 2020
6
33

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Hai T Tran, Yuan Liu, Amado J Zurita, Ying Lin, Katherine L Baker-Neblett, Anne-Marie Martin, Robert A Figlin, Thomas E Hutson, Cora N Sternberg, Rafael G Amado,[...]. Lancet Oncol 2012
196
33


The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA).
P P Tak, L Spaeny-Dekking, M C Kraan, F C Breedveld, C J Froelich, C E Hack. Clin Exp Immunol 1999
119
33

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.
Kurt A Schalper, Michael Carleton, Ming Zhou, Tian Chen, Ye Feng, Shu-Pang Huang, Alice M Walsh, Vipul Baxi, Dimple Pandya, Timothy Baradet,[...]. Nat Med 2020
89
33

The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.
Yu Fujita, Shigehiro Yagishita, Keitaro Hagiwara, Yusuke Yoshioka, Nobuyoshi Kosaka, Fumitaka Takeshita, Tomohiro Fujiwara, Koji Tsuta, Hiroshi Nokihara, Tomohide Tamura,[...]. Mol Ther 2015
168
33

Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Sehui Kim, Moon-Young Kim, Jaemoon Koh, Heounjeong Go, Dong Soo Lee, Yoon Kyung Jeon, Doo Hyun Chung. Eur J Cancer 2015
108
33

High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
Dan Liu, Yi Huang, Lei Li, Juan Song, Li Zhang, Weimin Li. BMC Cancer 2017
30
33

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
33

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
Valsamo Anagnostou, Daniel C Bruhm, Noushin Niknafs, James R White, Xiaoshan M Shao, John William Sidhom, Julie Stein, Hua-Ling Tsai, Hao Wang, Zineb Belcaid,[...]. Cell Rep Med 2020
9
33

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
33


Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot,[...]. Lancet 2016
33

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
Marzia Del Re, Riccardo Marconcini, Giulia Pasquini, Eleonora Rofi, Caterina Vivaldi, Francesco Bloise, Giuliana Restante, Elena Arrigoni, Chiara Caparello, Maria Grazia Bianco,[...]. Br J Cancer 2018
103
33


Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.
Li-Juan Chen, Xing-Ya Li, Yan-Qiu Zhao, Wen-Jing Liu, Hui-Juan Wu, Jie Liu, Xiao-Qian Mu, Hong-Bo Wu. Pathol Res Pract 2017
22
33

Plasma levels of granzyme B are increased in patients with lipid-rich carotid plaques as determined by echogenicity.
Mona Skjelland, Annika E Michelsen, Kirsten Krohg-Sørensen, Bjørn Tennøe, Arve Dahl, Søren Bakke, Frank Brosstad, Jan K Damås, David Russell, Bente Halvorsen,[...]. Atherosclerosis 2007
30
33

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Yusuke Okuma, Yukio Hosomi, Yoshiro Nakahara, Kageaki Watanabe, Yukiko Sagawa, Sadamu Homma. Lung Cancer 2017
94
33

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Elizabeth A Punnoose, Siminder Atwal, Weiqun Liu, Rajiv Raja, Bernard M Fine, Brett G M Hughes, Rodney J Hicks, Garret M Hampton, Lukas C Amler, Andrea Pirzkall,[...]. Clin Cancer Res 2012
300
33

Elevation of plasma granzyme B levels after acute myocardial infarction.
Hideyuki Kondo, Yukihiro Hojo, Rie Tsuru, Yoshioki Nishimura, Hayato Shimizu, Nozomu Takahashi, Masahiro Hirose, Tomokazu Ikemoto, Ken-Ichi Ohya, Takaaki Katsuki,[...]. Circ J 2009
29
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.